|
1
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miglietta F, Bottosso M, Griguolo G, Dieci
MV and Guarneri V: Erratum to ‘Major advancements in metastatic
breast cancer treatment: When expanding options means prolonging
survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]. ESMO
Open. 7:1004722022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cetin B, Wabl CA and Gumusay O: CDK4/6
inhibitors: Mechanisms of resistance and potential biomarkers of
responsiveness in breast cancer. Future Oncol. 18:1143–1157. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hortobagyi GN: Ribociclib for the
first-line treatment of advanced hormone receptor-positive breast
cancer: A review of subgroup analyses from the MONALEESA-2 trial.
Breast Cancer Res. 20:1232018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caschera L, Lazzara A, Piergallini L,
Ricci D, Tuscano B and Vanzulli A: Contrast agents in diagnostic
imaging: Present and future. Pharmacol Res. 110:65–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matamala N, Vargas MT, González-Cámpora R,
Miñambres R, Arias J, Menéndez P, Andrés-León E, Gómez-López G,
Yanowsky K, Calvete-Candenas J, et al: Tumor microRNA expression
profiling identifies circulating microRNAs for early breast cancer
detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Leva G and Croce CM: Roles of small
RNAs in tumor formation. Trends Mol Med. 16:257–267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andrikopoulou A, Shalit A, Zografos E,
Koutsoukos K, Korakiti AM, Liontos M, Dimopoulos MA and Zagouri F:
MicroRNAs as potential predictors of response to CDK4/6 inhibitor
treatment. Cancers (Basel). 13:41142021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ji W, Zhang W, Wang X, Shi Y, Yang F, Xie
H, Zhou W, Wang S and Guan X: c-myc regulates the sensitivity of
breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis.
Cell Death Dis. 11:7602020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qattan A, Intabli H, Alkhayal W, Eltabache
C, Tweigieri T and Amer SB: Robust expression of tumor suppressor
miRNA's let-7 and miR-195 detected in plasma of Saudi female breast
cancer patients. BMC Cancer. 17:7992017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eichelser C, Flesch-Janys D, Chang-Claude
J, Pantel K and Schwarzenbach H: Deregulated serum concentrations
of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and
miR-373 in human breast cancer development and progression. Clin
Chem. 59:1489–1496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gary JM, Simmons JK, Xu J, Zhang S, Peat
TJ, Watson N, Gamache BJ, Zhang K, Kovalchuk AL, Michalowski AM, et
al: Hypomorphic mTOR downregulates CDK6 and Delays Thymic Pre-T LBL
tumorigenesis. Mol Cancer Ther. 19:2221–2232. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodriguez-Otero P, Román-Gómez J,
Vilas-Zornoza A, José-Eneriz ES, Martín-Palanco V, Rifón J, Torres
A, Calasanz MJ, Agirre X and Prosper F: Deregulation of FGFR1 and
CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring
epigenetic modifications of the MIR9 family. Br J Haematol.
155:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakai A, Saitow F, Maruyama M, Miyake N,
Miyake K, Shimada T, Okada T and Suzuki H: MicroRNA cluster
miR-17-92 regulates multiple functionally related voltage-gated
potassium channels in chronic neuropathic pain. Nat Commun.
8:160792017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li M, Xiao A, Floyd D, Olmez I, Lee J,
Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I and Purow B:
CDK4/6 inhibition is more active against the glioblastoma proneural
subtype. Oncotarget. 8:55319–55331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thangavel C, Boopathi E, Ertel A, Lim M,
Addya S, Fortina P, Witkiewicz AK and Knudsen ES: Regulation of
miR106b cluster through the RB pathway: Mechanism and functional
targets. Cell Cycle. 12:98–111. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agirre X, Vilas-Zornoza A, Jiménez-Velasco
A, Martin-Subero JI, Cordeu L, Gárate L, San José-Eneriz E,
Abizanda G, Rodríguez-Otero P, Fortes P, et al: Epigenetic
silencing of the tumor suppressor microRNA Hsa-miR-124a regulates
CDK6 expression and confers a poor prognosis in acute lymphoblastic
leukemia. Cancer Res. 69:4443–4453. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baldassari F, Zerbinati C, Galasso M,
Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia
S: Screen for microRNA and drug interactions in breast cancer cell
lines points to miR-126 as a modulator of CDK4/6 and PIK3CA
inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Citron F, Segatto I, Vinciguerra GLR,
Musco L, Russo F, Mungo G, D'Andrea S, Mattevi MC, Perin T,
Schiappacassi M, et al: Downregulation of miR-223 expression is an
early event during mammary transformation and confers resistance to
CDK4/6 inhibitors in luminal breast cancer. Cancer Res.
80:1064–1077. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Favero A, Segatto I, Perin T and Belletti
B: The many facets of miR-223 in cancer: Oncosuppressor, oncogenic
driver, therapeutic target, and biomarker of response. Wiley
Interdiscip Rev RNA. 12:e16592021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Liu J, Chen J, Wang H, Yang L, Chen
F, Fan S, Wang J, Shao B, Yin D, et al: A serum microRNA signature
predicts trastuzumab benefit in HER2-positive metastatic breast
cancer patients. Nat Commun. 9:16142018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaukoniemi KM, Rauhala HE, Scaravilli M,
Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL and
Visakorpi T: Epigenetically altered miR-193b targets cyclin D1 in
prostate cancer. Cancer Med. 4:1417–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bustos MA, Ono S, Marzese DM, Oyama T,
Iida Y, Cheung G, Nelson N, Hsu SC, Yu Q and Hoon DSB: MiR-200a
Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic
Melanoma. J Invest Dermatol. 137:1955–1964. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jayaraj R, Nayagam SG, Kar A, Sathyakumar
S, Mohammed H, Smiti M, Sabarimurugan S, Kumarasamy C,
Priyadharshini T, Gothandam KM, et al: Clinical theragnostic
relationship between drug-resistance specific mirna expressions,
chemotherapeutic resistance, and sensitivity in breast cancer: A
systematic review and Meta-Analysis. Cells. 8:12502019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Chen X, Han W, Ruan A, Chen L,
Wang R, Xu Z, Xiao P, Lu X, Zhao Y, et al: miR-200c Targets CDK2
and suppresses tumorigenesis in renal cell carcinoma. Mol Cancer
Res. 13:1567–1577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Safaei S, Amini M, Najjary S, Mokhtarzadeh
A, Bolandi N, Saeedi H, Alizadeh N, Javadrashid D and Baradaran B:
miR-200c increases the sensitivity of breast cancer cells to
Doxorubicin through downregulating MDR1 gene. Exp Mol Pathol.
125:1047532022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hildyard JCW and Wells DJ: Identification
and validation of quantitative PCR reference genes suitable for
normalizing expression in normal and dystrophic cell culture models
of myogenesis. PLoS Curr.
6:ecurrents.md.faafdde4bea8df4aa7d06cd5553119a6. 2014.PubMed/NCBI
|
|
34
|
Rinnerthaler G, Hackl H, Gampenrieder SP,
Hamacher F, Hufnagl C, Hauser-Kronberger C, Zehentmayr F, Fastner
G, Sedlmayer F, Mlineritsch B and Greil R: miR-16-5p Is a
Stably-Expressed housekeeping MicroRNA in breast cancer tissues
from primary tumors and from metastatic sites. Int J Mol Sci.
17:1562016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:RESEARCH00342002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pfaffl MW, Tichopad A, Prgomet C and
Neuvians TP: Determination of stable housekeeping genes,
differentially regulated target genes and sample integrity:
BestKeeper-Excel-based tool using pair-wise correlations.
Biotechnol Lett. 26:509–515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Radonić A, Thulke S, Mackay IM, Landt O,
Siegert W and Nitsche A: Guideline to reference gene selection for
quantitative real-time PCR. Biochem Biophys Res Commun.
313:856–862. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Andersen CL, Jensen JL and Ørntoft TF:
Normalization of real-time quantitative reverse transcription-PCR
data: A model-based variance estimation approach to identify genes
suited for normalization, applied to bladder and colon cancer data
sets. Cancer Res. 64:5245–5250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dheda K, Huggett JF, Bustin SA, Johnson
MA, Rook G and Zumla A: Validation of housekeeping genes for
normalizing RNA expression in real-time PCR. Biotechniques.
37:112–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schober P and Schwarte LA: Correlation
coefficients: Appropriate use and interpretation. Anesth Analg.
126:1763–1768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–656. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Duffy MJ: Biochemical markers in breast
cancer: Which ones are clinically useful? Clin Biochem. 34:347–352.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seale KN and Tkaczuk KHR: Circulating
biomarkers in breast cancer. Clin Breast Cancer. 22:e319–e331.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Song B, Wang C, Liu J, Wang X, Lv L, Wei
L, Xie L, Zheng Y and Song X: MicroRNA-21 regulates breast cancer
invasion partly by targeting tissue inhibitor of metalloproteinase
3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C,
Wang X, Luo Z, Wang J, Liu S, et al: microRNA-21 promotes breast
cancer proliferation and metastasis by targeting LZTFL1. BMC
Cancer. 19:7382019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jinling W, Sijing S, Jie Z and Guinian W:
Prognostic value of circulating microRNA-21 for breast cancer: A
systematic review and meta-analysis. Artif Cells Nanomed
Biotechnol. 45:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rossi L, Bonmassar E and Faraoni I:
Modification of miR gene expression pattern in human colon cancer
cells following exposure to 5-fluorouracil in vitro. Pharmacol Res.
56:248–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yu Y, Liao H, Xie R, Zhang Y, Zheng R,
Chen J and Zhang B: Overexpression of miRNA-3613-3p enhances the
sensitivity of triple negative breast cancer to CDK4/6 inhibitor
palbociclib. Front Oncol. 10:5908132020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
van Zweeden AA, Opperman RCM, Honeywell
RJ, Peters GJ, Verheul HMW, van der Vliet HJ and Poel D: The
prognostic impact of circulating miRNAs in patients with advanced
esophagogastric cancer during palliative chemotherapy. Cancer Treat
Res Commun. 27:1003712021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiao W, Zhong Y, Wu L, Yang D, Ye S and
Zhang M: Prognostic value of microRNAs in lung cancer: A systematic
review and meta-analysis. Mol Clin Oncol. 10:67–77. 2019.PubMed/NCBI
|
|
52
|
Sahlberg KK, Bottai G, Naume B, Burwinkel
B, Calin GA, Børresen-Dale AL and Santarpia L: A serum MicroRNA
signature predicts tumor relapse and survival in triple-negative
breast cancer patients. Clin Cancer Res. 21:1207–1214. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Piña-Sánchez P, Valdez-Salazar HA and
Ruiz-Tachiquín ME: Circulating microRNAs and their role in the
immune response in triple-negative breast cancer. Oncol Lett.
20:224:2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tampellini M, Berruti A, Bitossi R,
Gorzegno G, Alabiso I, Bottini A, Farris A, Donadio M, Sarobba MG,
Manzin E, et al: Prognostic significance of changes in CA 15-3
serum levels during chemotherapy in metastatic breast cancer
patients. Breast Cancer Res Treat. 98:241–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
De Cock L, Heylen J, Wildiers A, Punie K,
Smeets A, Weltens C, Neven P, Billen J, Laenen A and Wildiers H:
Detection of secondary metastatic breast cancer by measurement of
plasma CA 15.3. ESMO Open. 6:1002032021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yerushalmi R, Tyldesley S, Kennecke H,
Speers C, Woods R, Knight B and Gelmon KA: Tumor markers in
metastatic breast cancer subtypes: Frequency of elevation and
correlation with outcome. Ann Oncol. 23:338–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yang Y, Zhang H, Zhang M, Meng Q, Cai L
and Zhang Q: Elevation of serum CEA and CA15-3 levels during
antitumor therapy predicts poor therapeutic response in advanced
breast cancer patients. Oncol Lett. 14:7549–7556. 2017.PubMed/NCBI
|
|
58
|
Fu J, Su X, Li Z, Deng L, Liu X, Feng X
and Peng J: HGF/c-MET pathway in cancer: From molecular
characterization to clinical evidence. Oncogene. 40:4625–4651.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Faiella A, Riccardi F, Cartenì G,
Chiurazzi M and Onofrio L: The Emerging Role of c-met in
carcinogenesis and clinical implications as a possible therapeutic
target. J Oncol. 2022:51791822022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou FH, Downton T, Freelander A, Hurwitz
J, Caldon CE and Lim E: CDK4/6 inhibitor resistance in estrogen
receptor positive breast cancer, a 2023 perspective. Front Cell Dev
Biol. 11:11487922023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yan S, Jiao X, Zou H and Li K: Prognostic
significance of c-Met in breast cancer: A meta-analysis of 6010
cases. Diagn Pathol. 10:622015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ho-Yen CM, Jones JL and Kermorgant S: The
clinical and functional significance of c-Met in breast cancer: A
review. Breast Cancer Res. 17:522015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Iovino F, Diana A, Carlino F, Ferraraccio
F, Antoniol G, Fisone F, Perrone A, Zito Marino F, Panarese I,
Tathode MS, et al: Expression of c-MET in estrogen receptor
positive and HER2 negative resected breast cancer correlated with a
poor prognosis. J Clin Med. 11:69872022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zearo S, Kim E, Zhu Y, Zhao JT, Sidhu SB,
Robinson BG and Soon PSh: MicroRNA-484 is more highly expressed in
serum of early breast cancer patients compared to healthy
volunteers. BMC Cancer. 14:2002014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li M, Zou X, Xia T, Wang T, Liu P, Zhou X,
Wang S and Zhu W: A five-miRNA panel in plasma was identified for
breast cancer diagnosis. Cancer Med. 8:7006–7017. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sarhadi VK and Armengol G: Molecular
biomarkers in cancer. Biomolecules. 12:10212022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Khan H, Shah MR, Barek J and Malik MI:
Cancer biomarkers and their biosensors: A comprehensive review.
TrAC Trends Anal Chem. 158:1168132023. View Article : Google Scholar
|
